The drug, also known as venglustat, targets the buildup of fatty substances called glycosphingolipids. Sanofi said it is designed to act across the blood-brain barrier. Type 3 is one of the three major forms of Gaucher disease; according to the FDA, harmful substances build up in the brain and nervous system, and symptoms can worsen over time.
Sanofi said a late-stage clinical trial found significant improvements in certain neurological manifestations, including cognitive deficits and difficulty with coordination and balance. The company did not provide further trial details in its announcement.
Infilbray carries warnings and precautions for suicidal ideation and behavior, clouding of vision in younger patients, and adverse effects on fetal development during pregnancy, Sanofi said.





Comments (0)
No comments yet. Be the first!